Skip to main content

Table 2 Demographics, clinical characteristics and outcome (week 24) of the study populations

From: Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)

ParameterSub-parameterImmediate treatmentDeferred treatmentp-value (if applicable)
Eventa (frequency row %)No event22 (70.97)21 (70.00)0.934 (computed by Chi-square)
Event9 (29.03)9 (30.00)
Hospitalization (days)Mean (absolute)33.2 ± 19.134.57 ± 23.60.6125 (computed by t-test)
Range (absolute)141205
Incidence of IRIS (%)Yes11 (35.48)10 (33.33)0.8597 (computed by Chi-square)
No20 (64.52)20 (66.67)
Virological outcome week 24 (more than 400 or 50 copies/mL)Number of patients with HIV RNA > 50 cop/mL12120.6740 (computed by Chi-square)
With HIV RNA > 400 cop/mL111.0 (computed by Fisher’s Exact test)
Immunological outcome (week 24): CD4 cellsAbsolute mean126 (± 42.1)137 (± 44.0)0.6421 (computed by t-test)
Delta mean9995
Quality of lifeSF 36 body score (sum of scores)570657720.7978
SF 36 psychological score (sum of scores)562251060.7978 (each computed by Wilcoxon test)
AE-severity by treatment (%)Grade 1 event61 (22.26)73 (26.64)0.4682 (computed by Fisher’s Exact test)
Grade 2 event53 (19.34)55 (20.07)
Grade 3 event6 (2.19)11 (4.01)
Grade 4 event3 (1.09)6 (2.19)
Unknown severity1 (0.38)5 (1.82)
Total124 (45.26)150 (54.74) 
PCP 4 events6 events0.6372 (number of events between TE/PCP; computed by Chi-square)
TE 5 events3 events
  1. Italicized values are standard-deviations of the mean-values
  2. aDefinition of event: death, all new or relapsing OI, other grade 4 (G4) clinical endpoint within 24 weeks (see “Methods” section)